For example, the ABL1 T315I missense mutation in the BCR-ABL fusion predicts poor response to imatinib, a tyrosine kinase inhibitor that would otherwise effectively target BCR-ABL, in patients with chronic myeloid leukemia [10]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.